Detalhe da pesquisa
1.
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab
; 24(9): 1840-1849, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35589610
2.
Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients.
Am J Transplant
; 21(11): 3714-3724, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34033222
3.
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
Diabetes Care
; 43(4): 710-718, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32019854
4.
CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.
Diabetes
; 64(4): 1329-40, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25315007
5.
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
J Clin Invest
; 122(10): 3647-51, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22996693